ENZON PHARMACEUTICALS INC
ENZN
ENZN was delisted on the 19th of May, 2016.
10 hedge funds and large institutions have $202K invested in ENZON PHARMACEUTICALS INC in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 32 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
75% less funds holding
Funds holding: 40 → 10 (-30)
94% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 32
97% less capital invested
Capital invested by funds: $8.07M → $202K (-$7.87M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
Ancora Advisors
Cleveland,
Ohio
|
+$24.8K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$4.38K |
| 3 |
TCM
Tradewinds Capital Management
Bellingham,
Washington
|
+$99 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Icahn Carl
Sunny Isles Beach,
Florida
|
-$2.77M |
| 2 |
Renaissance Technologies
New York
|
-$1.48M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.33M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$706K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$340K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
26
Spark Investment Management
New York
| – | -$11K | -25,100 | Closed |
|
27
Charles Schwab
San Francisco,
California
| – | -$11K | -21,300 | Closed |
|
28
Two Sigma Advisers
New York
| – | -$7K | -14,700 | Closed |
|
|
BJ
29
BlackRock Japan
Tokyo,
Japan
| – | -$4K | -9,274 | Closed |
|
30
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$4K | -9,098 | Closed |
|
|
AIG
31
American International Group
New York
| – | -$2K | -5,000 | Closed |
|
32
Morgan Stanley
New York
| – | -$2K | -4,600 | Closed |
|
33
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$1K | -1,758 | Closed |
|
|
TCM
34
Tradewinds Capital Management
Bellingham,
Washington
| – | +$99 | +200 | New |
|
ENZN Hedge Fund Activity: Q2 2016 in Review
10 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in ENZON PHARMACEUTICALS INC (ENZN) for Q2 2016, worth a combined $202K — down 97% from $8.07M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of ENZN and 2 opened new positions — a net loss of 30 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Ancora Advisors, opening a new position worth an estimated $24.8K. The largest seller was Icahn Carl, exiting entirely with an estimated $2.77M sold.
- 10 institutional investors held ENZON PHARMACEUTICALS INC (ENZN) as of Q2 2016, down from 40 in Q1 2016.
- Funds reported $202K of ENZON PHARMACEUTICALS INC stock for Q2 2016, down 97% quarter-over-quarter.
- 2 funds opened new ENZON PHARMACEUTICALS INC positions in Q2 2016 and 32 closed out, a net change of -30 holders.
- The largest ENZON PHARMACEUTICALS INC buyer in Q2 2016 was Ancora Advisors, an estimated $24.8K added.
- The largest ENZON PHARMACEUTICALS INC seller in Q2 2016 was Icahn Carl, an estimated $2.77M sold.
Based on aggregated 13F filings for Q2 2016.